Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells 472 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 472 shares of Hims & Hers Health stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $29.58, for a total value of $13,961.76. Following the completion of the sale, the insider now directly owns 17,331 shares in the company, valued at $512,650.98. This trade represents a 2.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Irene Becklund also recently made the following trade(s):

• On Monday, November 18th, Irene Becklund sold 472 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.42, for a total transaction of $9,166.24.

Hims & Hers Health Trading Down 0.4 %

HIMS traded down $0.13 during trading hours on Tuesday, hitting $31.12. The company’s stock had a trading volume of 14,635,490 shares, compared to its average volume of 9,946,161. Hims & Hers Health, Inc. has a fifty-two week low of $8.09 and a fifty-two week high of $35.02. The firm has a market capitalization of $6.80 billion, a PE ratio of 70.09 and a beta of 1.25. The company has a 50-day simple moving average of $25.02 and a 200 day simple moving average of $21.06.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the prior year, the company earned ($0.04) EPS. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on HIMS shares. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their target price for the company from $32.00 to $18.00 in a research report on Thursday, November 14th. TD Cowen reissued a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Morgan Stanley assumed coverage on shares of Hims & Hers Health in a report on Tuesday. They issued an “overweight” rating and a $42.00 price target on the stock. Piper Sandler reiterated a “neutral” rating and set a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Finally, Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $22.80.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC raised its position in Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after purchasing an additional 3,205,108 shares during the last quarter. State Street Corp lifted its stake in Hims & Hers Health by 4.7% in the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after buying an additional 206,078 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 12.7% in the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after buying an additional 482,177 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after buying an additional 883,230 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Hims & Hers Health by 15.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after acquiring an additional 218,566 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.